baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BASILEA PHARMACEUTICA-REG/ CH0011432447 /

27/09/2024 11:50:45	Chg. -0.10	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
47.10CHF	-0.21%	119 Turnover: 5,607.15	-Bid Size: -	-Ask Size: -	617.66 mill.CHF	-	54.20

GlobeNewswire 27/08 European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...

GlobeNewswire 21/08 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...

GlobeNewswire 13/08 Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...

GlobeNewswire 20/06 Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

GlobeNewswire 16/05 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...

GlobeNewswire 03/05 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

GlobeNewswire 24/04 Basilea shareholders approve all proposals of the board of directors at the annual general meeting

GlobeNewswire 09/04 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

GlobeNewswire 04/04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...

GlobeNewswire 11/03 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...

GlobeNewswire 13/02 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...

GlobeNewswire 19/01 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

GlobeNewswire 15/01 Basilea announces acquisition of preclinical antibiotics program from Spexis

GlobeNewswire 05/01 Basilea provides portfolio status update

GlobeNewswire 11/12/2023 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...

GlobeNewswire 20/11/2023 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...

GlobeNewswire 13/11/2023 Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

GlobeNewswire 31/10/2023 Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...

GlobeNewswire 19/10/2023 Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...

GlobeNewswire 17/10/2023 Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

GlobeNewswire 02/10/2023 Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

GlobeNewswire 28/09/2023 Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...

GlobeNewswire 15/08/2023 Basilea reports strong revenue and profit growth in first half-year 2023

GlobeNewswire 08/03/2022 Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...

GlobeNewswire 15/02/2022 Basilea to become a leading anti-infectives company backed by strong financial results 2021

BASILEA PHARMACEUTICA-REG/ CH0011432447 /

If you wish to receive reply to your feedback, please provide your email address.